Skip to main content

Yarrow Bioscience, Inc.

corporate_fare Company Profile

Yarrow Bioscience, Inc.

YARW·NASDAQ·Life Sciences·CIK 0001566044

Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune thyroid diseases. The company's primary product candidate is YB-101, a humanized monoclonal antibody. YB-101 is designed to target the thyroid-stimulating hormone receptor (TSHR) and is being developed for the treatment of Graves' disease and thyroid eye disease. Yarrow Bioscience, Inc. was incorporated in 2025 and operates from its base in New York, New York.

Yarrow Bioscience, Inc. (NASDAQ:YARW) is a publicly traded company in the Life Sciences sector. Wiseek monitors YARW SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • OrbiMed reveals 9.97% stake in Yarrow Bioscience after merger, plus warrants for 4.7 million shares

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$570K
Net Income
-$26.48M
Diluted EPS
-$0.62
Op. Cash Flow
-$33.12M
Free Cash Flow
-$33.12M
Operating Income
-$29.75M
Cash & Equivalents
$24.03M
Debt / Equity
0.00×
Net Margin
-46.46×
Shares Outstanding
33.32M sh
Source: 10-K · filed 2026-02-27 · accession 0001566044-26-000002
$37.7
52-week range · as of 2026-08-06 $14.03 – $46.95
Market cap
$100.65M
Volume
26K (0.7× avg)
3-mo avg 35.3K
Live data · 2026-08-06 02:00 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed YARW - Latest Insights

YARW
Aug 05, 2026, 9:08 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
OrbiMed reveals 9.97% stake in Yarrow Bioscience after merger, plus warrants for 4.7 million shares
Price at Filing: $37.70
Real-time Price: $37.70 info
Change: $0 (0%) info
Market Cap: $100.651M info
Sentiment: Neutral
View Wiseek Article